Science
RNA therapeutics engineered for the vasculature
Vascular aging is not inevitable. By targeting the genetic drivers of vascular decline, we are unlocking
a future where cardiovascular disease is preventable and reversible. Our precision RNA therapeutics
reprogram vascular biology and restore youth-like function.
- Target-Site Blockers (TSBs) — Disarm microRNA repression at target mRNA sites to increase protective gene expression.
- Antisense Oligonucleotides (ASOs) — Selectively silence pathogenic transcripts that drive inflammation and plaque growth.
These therapies selectively modulate protective and pathogenic gene pathways involved in vascular regeneration,
lipid handling, inflammation, and vascular cell health.
Platform Strengths
- Proprietary miRNA-targeting strategy
- Cell-specific vascular targeting
- Validated gene targets with strong biology
- Scalable across cardiovascular indications
- Designed for lipid- and nanoparticle-based delivery
